Author: equipe

14 May CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

/*! elementor - v3.21.0 - 08-05-2024 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Positive changes in prognostic biomarkers including...

06 May CellProthera to share results from its Phase I/IIb study investigating the safety and efficacy of ProtheraCytes (CD34+ expanded stem cells) in Acute Myocardial Infarction

Mulhouse, France, April 23 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases will...

29 Feb CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming autologous stem cell trials in ischemic diseases

• Upcoming clinical trials, led by stem cell pioneer Professor Takayuki Asahara, will use CellProthera’s StemXpand® and StemPack® technology to manufacture endothelial progenitor cells (EPCs)
• This collaboration is the first to bring CellProthera’s manufacturing systems to Japan, following successful use of the systems in clinical trials in Europe

07 Nov CVCT-CardioVascular Clinical Trialists Washington DC 30 Nov-2 Dec

CellProthera will participate in the Global CardioVascular Clinical Trialists Forum (CVCT) on November 30 - December 2nd,...